Bruton's tyrosine kinase as anti-cancer drug target

US9637554B2 · kind B2 · utility

Assignee

• The Research Foundation for The State University of New York · US

Inventors

• Douglas S. Conklin · Huntington Bay, US
• Cheryl L. Eifert · Watertown, US
• Antonis Kourtidis · St. Augustine, US
• Xianhui Wang · Albany, US
• Leila Kokabee · Albany, US

Key dates

• Filing date: Aug 4, 2015
• Grant date: May 2, 2017
• Expiry date: Aug 4, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/9121
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Receptor protein kinases (RPTKs) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets. A large-scale loss-of-function analysis of tyrosine kinases using RNA interference in the clinically relevant Erb-B2 positive, BT474 breast cancer cell line showed that Bruton's tyrosine kinase (BTK), a cytosolic, non-receptor tyrosine kinase that has been extensively studied for its role in B cell development, is required, in altered form, for BT474 breast cancer survival. This alternative form contains an amino-terminal extension that is also present in tumorigenic breast cells at significantly higher levels than in normal breast cells.